January 17, 2025
Shawn, a 49-year-old native of Columbus, Ohio, after injecting fentanyl at OnPoint NYC, one of just three supervised consumption sites currently operating in the United States.
Chantal Heijnen for STAT

An NYC nonprofit has reversed 1,700 overdoses since 2021. Under Trump, it faces an uncertain future

OnPoint NYC’s supervised consumption site offers lifesaving harm reduction services, reversing 1,700 overdoses since 2021, but faces political headwinds.

By Lev Facher


STAT+ | Medicare announces plan to negotiate prices of diabetes, weight loss drugs

Weight loss drug on list of 15 whose prices will be negotiated under President Biden’s Inflation Reduction Act. Also on the list: Trelegy Ellipta, Xtandi.

By Rachel Cohrs Zhang


Alcohol labels should carry ‘Alcohol Facts’ box listing nutrition and allergens, regulator says

The Treasury bureau that regulates alcohol mandates that nutrition information and allergens should be on alcoholic beverage labels.

By Isabella Cueto



President Biden, shown in his Wednesday farewell address to the nation from the Oval Office, oversaw a marked shift toward harm reduction for addiction.
MANDEL NGAN/POOL/AFP via Getty Images

Biden administration moves to expand, preserve access to addiction treatments as term expires

Over the last four years, the White House showed unprecedented support for ensuring access to addiction treatment and harm reduction.

By Lev Facher


STAT+ | A reporter’s JPM notebook: a look ahead for biopharma VC investing

J.P. Morgan Healthcare Conference offers clues at what's next in biotech, pharma investments. VCs eye autoimmune disorders, bone density, new pain drugs.

By Allison DeAngelis


STAT+ | High-dose Wegovy leads to substantial weight loss in trial, but falls short of Zepbound

Novo Nordisk has been facing pressure from investors to develop drugs that can deliver greater weight loss than those made by Eli Lilly.

By Elaine Chen


Adobe

STAT+ | Online marketing for compounded GLP-1 drugs overstates benefits and underplays risks

New analysis in JAMA Health Forum finds nearly half the compounded GLP-1 websites didn’t include information on adverse effects, warnings, contraindications.

By Katie Palmer


STAT+ | Florida hospital CEO says Medicare site-neutral payment reform ‘makes some sense’

Tens of billions of dollars in hospital revenue could be at stake if Medicare cuts payments for outpatient care.

By Bob Herman


Opinion: Trump nominees for health positions should fail the ‘Fauci test’

The key to constructive vetting of RFK Jr. and others is to find the faint bipartisan signal of consensus buried in the noise of polarized discord.

By Steven Phillips


More around STAT
Check out more exclusive coverage with a STAT+ subscription
Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

Enjoying Daily Recap? Tell us about your experience
Continue reading the latest health & science news with the STAT app
Download on the App Store or get it on Google Play
STAT
STAT, 1 Exchange Place, Boston, MA
©2025, All Rights Reserved.